期刊文献+

中美欧药用辅料监管比较分析 被引量:7

Comparison study of excipient regulations in China,the US and EU
原文传递
导出
摘要 药用辅料是影响药品安全的重要成分。本文通过上市许可、质量标准、生产和流通要求、供应链管理等方面,对比中国、美国、欧洲的药用监管和行业实践,以上市许可为主线分析三地区对药用辅料的质量标准、审评考虑、审批流程、生产和流通要求的异同。 Pharmaceutical excipients are important components affecting drug safety. This work compares excipient regulations and industry practices in China, the US and EU in registration, specification, GMP and GDP requirements and supply chain management, and analyzes the differences of specification, review consideration, review procedures, manufacture and distribution requirements in these three regions mainly from the perspective of registration, to provide references for regulatory agencies and industry organizations.
出处 《中国新药杂志》 CAS CSCD 北大核心 2012年第22期2612-2622,共11页 Chinese Journal of New Drugs
关键词 辅料监管 行业实践 上市许可 质量标准 生产和流通要求 供应链管理 excipient regulation industry practice registration GMP and GDP requirements supply chain management
  • 相关文献

参考文献45

  • 1JACKSON K, YOUNG D,PANTS. Drug-excipient interactions and their affect on absorption [ J ]. Pharm Sci Techno Today, 2000,3 ( 10 ) : 336 - 345.
  • 2WANG FJ,SAIDELMG, GAO JM. A mechanistic model of con- trolled drug release from polymer millirods: Effects of excipients and complex binding [ J ]. J Controlled Release, 2007,119 ( 1 ) : 111 - 120.
  • 3CHEN ML,STRAUGHN AB,SADRIEH N,et al. A modern view of excipient effects on bioequivalence: case study of sorbitol[ J]. Pharm Res ,2007,24 ( 1 ) :73 - 80.
  • 4KALINKOVA GN. Studies of beneficial interactions between ac- tive medicaments and excipients in pharmaceutical formulations [J]. lnt J Pharm,1999,157(1):1-15.
  • 5VEIGA F, TEIXEIRA D, KEDZIEREWICZ F, et al. Inclusion complexation of tolbutamide with beta-cyclodextrin and hydroxypropyl-beta-cyclodextrin [ J ]. lnt J Pharm, 1996, 129 (1 -2) :63 -71.
  • 6KO0 0 MY,VARIA SA. Case studies with new excipients: de- velopment, implementation and regulatory approval[ J]. Ther De- liv,2011,2(7) :949 -956.
  • 7FDA. Guidance for Industry Nonclinical Studies for the Safety E- valuation of Pharmaceutical Excipients[S]. 2005.
  • 8CHRISTOPHER CD. IPEC-Americas novel excipient safety eval- uation procedure[ J]. 2010.
  • 9浙江省食品药品监督管理局.浙江省药用辅料使用管理暂行规定[EB/OL].(2006-07-17).http://www.zjfda.gov.cn/news/detail/691.html.
  • 10国家食品药品监督管理局.药用辅料注册申报资料要求,食药监注函[2005]6l[EB/OL].(2005-06-21).http://WWW.sda.gov.cn/WS01/CL0844/10409.html.

二级参考文献33

  • 1.中国药典[S].,2005年版.附录85.
  • 2国家食品药品监督管理局编.药物研究技术指导原则[M].北京:中国医药科技出版社,2006-2007.
  • 3中国药典[S].2010.
  • 4国家食品药品监督管理局.关于印发《药用辅料生产质量管理规范》的通知[Z].国食药监安[2006] 120号,2006.
  • 5新药审批办法[S].国家药品监督管理局令第2号,1999.
  • 6国家食品药品监督管理局药品注册司.关于印发药用辅料注册申报资料要求的函[Z].食药监注[2005] 61号,2005.
  • 7国家食品药品监督管理局.药用辅料注册管理办法(征求意见稿)[EB/OL].[2010-10-10].http://www.drugunabuse.com/list-new,asp?id=760.
  • 8美国药典委员会.美国药典(USP32-NF27)[S].2008.
  • 9日本公定书协会.日本药局方(JPl5).15版[S].2006.
  • 10欧洲药典委员会.欧洲药典.55版[S].2005.

共引文献51

同被引文献34

  • 1张庆生.完善药品标准体系建设,关注药用辅料标准[J].中国药师,2005,8(12):1034-1035. 被引量:6
  • 2国家食品药品监督管理局.关于《药用辅料管理办法》(征求意见稿)网上征求意见的函[EB/OL].[2011-02-21].ht-tp://www.sda.gov.cn/WS01/CL0055/10420.html.
  • 3Certification of suitability to the monographs of the European Pharmacopoeia[ Z].
  • 421 CFR 170,182b-186 [EB/OL]. http://www, accessdata, fda. gov/scripts/edrh/efdocs/cfcfr/CFRSeareh, elm? CFRPart = 170.
  • 5Guidelines For Drug Master File[-EB/OL]. http://www, fda. gov/Drugs/Guidance Compliance Regulatory Information/Guid- ances/ucm 122886. htm.
  • 6宋民宪,夏军平.部分省市药用辅料使用情况调研报告[J].首届药用辅料(国际)学术研讨会论文集,2004.
  • 7安徽省医药行业协会.我国药用辅料的产业现状及发展趋势[EB/OL]. [2011-11 -20]. http: //www. ah ppa. cn/por- tal. php? mod=viewaid=355.
  • 8国际药用辅料网.对我国药用辅料工业发展的浅见[EB/OL].[2009-03 12]. http: /,/www. phexcorru cn/bbs/Index, asp.
  • 9国家食品药品监督管理总局.关于印发加强药用辅料监督管理有关规定的通知[EB/OL].[2012-08-01].http://www.sda.gov,ca/WS01/Ci.0844/73959.html.
  • 10宋民宪.药用辅料配角时代的消亡[N].医药经济报,2008-06-07(011).

引证文献7

二级引证文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部